Ann: Publication of Invex IIH Phase II Pressure Trial Results, page-10

I think that is the strategy they are running with indeed; prior to IIH trial read out start secondary indication work streams that with the same MOA will mean the upside of the potential Phase III success will be magnified, and the following M&A bids to include a portion of the TAM of that secondary indication as priced in as a higher probability of success for the Phase II/III for biotech valuation purposes.

This would achieve the magnified upside, without the dilution, and achieve the lowest risk, highest return and in the shortest time period for shareholders.

Just makes sense to go this route, and it pairs well with the IXC management style of conservative financial management.